MX2023004479A - Sistema de vector multiple y sus usos. - Google Patents

Sistema de vector multiple y sus usos.

Info

Publication number
MX2023004479A
MX2023004479A MX2023004479A MX2023004479A MX2023004479A MX 2023004479 A MX2023004479 A MX 2023004479A MX 2023004479 A MX2023004479 A MX 2023004479A MX 2023004479 A MX2023004479 A MX 2023004479A MX 2023004479 A MX2023004479 A MX 2023004479A
Authority
MX
Mexico
Prior art keywords
vector system
multiple vector
constructs
vectors
allow
Prior art date
Application number
MX2023004479A
Other languages
English (en)
Inventor
Ivana Trapani
Alberto Auricchio
Pasqualina Colella
Original Assignee
Fond Telethon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fond Telethon filed Critical Fond Telethon
Publication of MX2023004479A publication Critical patent/MX2023004479A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/40—Systems of functionally co-operating vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C12N2840/445—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor for trans-splicing, e.g. polypyrimidine tract, branch point splicing

Abstract

La presente invención se refiere a constructos, vectores, células hospederas relativas y composiciones farmacéuticas que permiten una terapia genética eficaz, en particular de genes mayores a 5Kb.
MX2023004479A 2015-03-03 2017-08-31 Sistema de vector multiple y sus usos. MX2023004479A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562127463P 2015-03-03 2015-03-03

Publications (1)

Publication Number Publication Date
MX2023004479A true MX2023004479A (es) 2023-05-04

Family

ID=56849204

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017011255A MX2017011255A (es) 2015-03-03 2016-03-03 Sistema de vector múltiple y sus usos.
MX2023004479A MX2023004479A (es) 2015-03-03 2017-08-31 Sistema de vector multiple y sus usos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017011255A MX2017011255A (es) 2015-03-03 2016-03-03 Sistema de vector múltiple y sus usos.

Country Status (17)

Country Link
US (2) US20180327779A1 (es)
EP (2) EP3265571B1 (es)
JP (2) JP7182873B2 (es)
KR (1) KR102240180B1 (es)
CN (1) CN107466325A (es)
AU (1) AU2016227668B2 (es)
BR (1) BR112017018728A2 (es)
CA (1) CA2979120A1 (es)
DK (1) DK3265571T3 (es)
ES (1) ES2919880T3 (es)
HR (1) HRP20220776T1 (es)
MX (2) MX2017011255A (es)
PL (1) PL3265571T3 (es)
PT (1) PT3265571T (es)
RS (1) RS63416B1 (es)
SI (1) SI3265571T1 (es)
WO (1) WO2016139321A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3719134B1 (en) * 2015-03-11 2023-08-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Rp2 vectors for treating x-linked retinitis pigmentosa
US11072803B2 (en) 2015-12-22 2021-07-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Hybrid dual recombinant AAV vector systems for gene therapy
JP2019530737A (ja) 2016-08-23 2019-10-24 アコーオス インコーポレイテッド ヒト対象において非加齢性聴力障害を治療するための組成物および方法
CN110892062A (zh) * 2017-05-05 2020-03-17 佛罗里达大学研究基金会 表达耳畸蛋白的组合物和方法
CN113056561A (zh) * 2018-04-05 2021-06-29 牛津大学科技创新有限公司 用于治疗黄斑营养不良的组合物和方法
EP3781213A4 (en) * 2018-04-17 2022-10-19 The Trustees of the University of Pennsylvania TRANS-SPLICE MOLECULES
US11660353B2 (en) 2018-04-27 2023-05-30 Decibel Therapeutics, Inc. Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
EP3867387A2 (en) * 2018-10-15 2021-08-25 Fondazione Telethon Intein proteins and uses thereof
EP3870148A4 (en) * 2018-10-25 2022-11-09 Takeda Pharmaceutical Company Limited AAV TRIPLE PLASMID SYSTEM
EP3956453A4 (en) * 2019-04-19 2023-02-22 University of Massachusetts GENE THERAPIES FOR USHER SYNDROME (USH1B)
US20220315948A1 (en) * 2019-04-26 2022-10-06 President And Fellows Of Harvard College Aav vectors encoding mini-pcdh15 and uses thereof
WO2021116138A1 (en) * 2019-12-09 2021-06-17 Ucl Business Ltd Gene therapy composition and treatment for myh7-linked cardiomyopathy
EP4100518A2 (en) * 2020-02-07 2022-12-14 The Children's Medical Center Corporation Large gene vectors and delivery and uses thereof
AU2021225035A1 (en) 2020-02-21 2022-10-13 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
CN112501209B (zh) * 2020-12-07 2024-02-13 和元生物技术（上海）股份有限公司 外源基因可控表达的腺相关病毒包装方法
CA3218195A1 (en) * 2021-05-07 2022-11-10 Robin Ali Abca4 genome editing

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827702A (en) 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
GB9720465D0 (en) * 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
US6106826A (en) 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
DK1071806T3 (da) 1998-04-24 2004-07-19 Univ Florida Rekombinant adeno-associeret virus-vektor, der koder for alpha-1-antitrypsin i genterapi
US6967018B2 (en) 2002-01-11 2005-11-22 Applied Genetic Technologies Corporation Adiponectin gene therapy
WO2003088916A2 (en) * 2002-04-19 2003-10-30 Georgia Tech Research Corporation Compositions and methods for the acceleration of protein secretion dynamics
WO2006036465A2 (en) 2004-09-03 2006-04-06 University Of Florida Compositions and methods for treating cystic fibrosis
JP4948845B2 (ja) * 2006-02-08 2012-06-06 財団法人 東京都医学総合研究所 神経変性疾患治療用物質のスクリーニング方法
AU2007223427A1 (en) * 2006-03-01 2007-09-13 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
WO2007127428A2 (en) 2006-04-28 2007-11-08 University Of Florida Research Foundation, Inc. Double-stranded/self-complementary vectors with a truncated cba promoter and methods of gene delivery
US8236557B2 (en) * 2008-05-28 2012-08-07 University Of Missouri-Columbia Hybrid-AAV vectors to deliver large gene expression cassette
WO2010059763A1 (en) * 2008-11-19 2010-05-27 Amyris Biotechnologies, Inc. Compositions and methods for the assembly of polynucleotides
AU2010267963B2 (en) * 2009-07-02 2015-09-24 Merz Pharma Gmbh & Co. Kgaa Neurotoxins exhibiting shortened biological activity
ES2704677T3 (es) * 2013-04-18 2019-03-19 Fond Telethon Suministro eficaz de genes grandes por vectores de AAV duales

Also Published As

Publication number Publication date
WO2016139321A1 (en) 2016-09-09
PL3265571T3 (pl) 2022-09-05
BR112017018728A2 (pt) 2018-04-17
DK3265571T3 (da) 2022-06-27
KR102240180B1 (ko) 2021-04-14
AU2016227668B2 (en) 2019-06-27
CN107466325A (zh) 2017-12-12
PT3265571T (pt) 2022-06-29
JP2018512125A (ja) 2018-05-17
MX2017011255A (es) 2018-08-01
JP7182873B2 (ja) 2022-12-05
EP3265571B1 (en) 2022-04-13
KR20170140185A (ko) 2017-12-20
EP4089172A3 (en) 2023-03-01
RS63416B1 (sr) 2022-08-31
EP4089172A2 (en) 2022-11-16
CA2979120A1 (en) 2016-09-09
AU2016227668A1 (en) 2017-08-31
ES2919880T3 (es) 2022-07-28
US20220002749A1 (en) 2022-01-06
US20180327779A1 (en) 2018-11-15
EP3265571A1 (en) 2018-01-10
HRP20220776T1 (hr) 2022-09-16
SI3265571T1 (sl) 2022-10-28
JP2022174192A (ja) 2022-11-22

Similar Documents

Publication Publication Date Title
MX2023004479A (es) Sistema de vector multiple y sus usos.
MX365711B (es) Administración efectiva de genes grandes por vectores aav duales.
MX2017014125A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX2022003116A (es) Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos.
IL272799A (en) Lipid nanoparticle formulations of non-viral capsid-free DNA vectors
MX2017007731A (es) Composiciones de detergente, variantes de lipasa y polinucleotidos que codifican las mismas.
MX2023003246A (es) Metodos y composiciones para atenuar las respuestas inmunes anti-vector de transferencia viral que modula la expresion de genes.
EP3741849A3 (en) Protease variants and polynucleotides encoding same
MX2019000140A (es) Variantes de xilanasa y polinucleotidos que las codifican.
EP3741848A3 (en) Protease variants and polynucleotides encoding same
EP4273238A3 (en) Compositions comprising polypeptides having xylanase activity and polypeptides having arabinofuranosidase activity
MX2021004391A (es) Proteinas inteinas y usos de las mismas.
MX2018008051A (es) Variantes de beta-glucanasa y polinucleotidos que las codifican.
PH12018500568A1 (en) Antisense nucleic acid
EP3964575A3 (en) Alpha-amylase variants and polynucleotides encoding same
CA3057899A1 (en) Diaphragm-specific nucleic acid regulatory elements and methods and use thereof
WO2016062875A3 (en) Glucoamylase variants and polynucleotides encoding same
EP3998341A3 (en) Adenoviral vectors
MX2022001017A (es) Composiciones y metodos para inhibir la expresion del gen de sintasa de acido 5'-aminolevulinico 1 (alas1).
SG11201705820UA (en) Gene expression system using stealthy rna, and gene introduction/expression vector including said rna
WO2018202921A3 (en) Nanostructured proteins and uses thereof
EP3373938A4 (en) NOVEL RNA-BASED VECTOR SYSTEM FOR TEMPORARY AND STABLE GENE EXPRESSION
EP3739045A3 (en) Cellobiohydrolase variants and polynucleotides encoding same
GB2572716B (en) Gene Therapy Vector System and Prodrug Genes
WO2016106432A3 (en) Endoglucanase variants and polynucleotides encoding same